About Nevro Corp

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. HF10 therapy has demonstrated the ability to reduce or eliminate opioids in =65% of patients across six peer-reviewed clinical studies. The Senza® System, Senza II™ System, and the Senza® Omnia™ System are the only SCS systems that deliver Nevro's proprietary HF10® therapy. Senza, Senza II, Senza Omnia, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.

CEO

D.Keith Grossman

Employees

843

Headquarters

1800 Bridge Pkwy
Redwood City, California 94065-1164
Phone: 16502510005
www.nevro.com

News

New Data Demonstrate the Health Economic Benefits of Nevro’s High-Frequency Spinal Cord Stimulation Therapy
Sep 18, 2023 16:04pm

Publications Show Reductions in Hospital Resource Utilization Associated with 10 kHz TherapySpinal Cord Stimulation for the Treatment of Painful Diabetic Neuropathy and Nonsurgical Refractory Back Pain REDWOOD CITY, Calif., Sept. 18, 2023 /PRNewswire/ — Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, […] The post New Data Demonstrate the Health Economic Benefits of Nevro’s High-Frequency Spinal Cord Stimulation Therapy appeared first on TodaysStocks.com .

Source:TodaysStocks.com

Nevro: Economic Realities Too Deep To Ignore, Downgrade To Hold
Sep 01, 2023 19:54pm

Nevro Corp., a medical device company, provides products for patients suffering from chronic pain. Find out why I revise my rating on NVRO stock a hold.

Source:Seeking Alpha

Citi maintains Nevro Corp at ''neutral'' with a price target of $21.00
Aug 21, 2023 09:19am

https://www.investing.com/news/pro/nevro-corp-receives-investment-bank-analyst-rating-update-3157961

Source:Investing.com

New 24-Month Data Shows Nevro''s SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic Neuropathy | NVRO Stock News
Aug 16, 2023 12:00pm

Evidence Published in Diabetes Research and Clinical Practice Shows 10 kHz Therapy Yields Lasting Pain Relief and Enhances

Source:Stock Titan

Nevro Announces New 24-Month Data Shows SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic Neuropathy
Aug 16, 2023 11:05am

https://www.investing.com/news/assorted/nevro-announces-new-24month-data-shows-scs-therapy-provides-highly-effective-longterm-relief-from-painful-diabetic-neuropathy-432SI-3155324

Source:Investing.com

New 24-Month Data Shows Nevro''s SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic Neuropathy
Aug 16, 2023 11:00am

Evidence Published in Diabetes Research and Clinical Practice Shows 10 kHz Therapy Yields Lasting Pain Relief and Enhances Health-Related Quality of Life and Sleep REDWOOD CITY, Calif., Aug. 16, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering…

Source:PR Newswire

Nevro Corp: Nevro announces launch of HFX Connect in Europe and CE marking of expanded labelling for the HFX SCS system.
Aug 10, 2023 08:54am

REDWOOD CITY, Calif., Aug. 10, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO) has announced today the launch of HFX Connect in Europe and CE marking of expanded labelling (Painful Diabetic Neuropat…

Source:Finanz Nachrichten

Nevro announces launch of HFX Connect in Europe and CE marking of expanded labelling for the HFX SCS system.
Aug 10, 2023 08:52am

REDWOOD CITY, Calif., Aug. 10, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO) has announced today the launch of HFX Connect in Europe and CE marking of expanded labelling (Painful Diabetic Neuropathy, PDN and Non-Surgical Back Pain, NSBP) for the HFX SCS system. The latest development from the global medical device company delivering comprehensive, life-changing solutions for the treatment of

Source:Wallstreet:Online